WO2000056351A3 - Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms - Google Patents

Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms Download PDF

Info

Publication number
WO2000056351A3
WO2000056351A3 PCT/US2000/006202 US0006202W WO0056351A3 WO 2000056351 A3 WO2000056351 A3 WO 2000056351A3 US 0006202 W US0006202 W US 0006202W WO 0056351 A3 WO0056351 A3 WO 0056351A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor suppressor
gemcitabine
treatment
neoplasms
suppressor gene
Prior art date
Application number
PCT/US2000/006202
Other languages
French (fr)
Other versions
WO2000056351A2 (en
Inventor
Loretta Lynn Nielsen
Jo Ann Horowitz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to AU37351/00A priority Critical patent/AU3735100A/en
Publication of WO2000056351A2 publication Critical patent/WO2000056351A2/en
Publication of WO2000056351A3 publication Critical patent/WO2000056351A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention describes novel methods of treating subjects afflicted with hyperproliferative diseases such as tumors or metastatic disease. In particular, this invention provides methods of treating cancer, comprising the use of gemcitabine in combination with a tumor suppressor gene or gene product. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and gemcitabine, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
PCT/US2000/006202 1999-03-19 2000-03-10 Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms WO2000056351A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37351/00A AU3735100A (en) 1999-03-19 2000-03-10 Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27301399A 1999-03-19 1999-03-19
US09/273,013 1999-03-19

Publications (2)

Publication Number Publication Date
WO2000056351A2 WO2000056351A2 (en) 2000-09-28
WO2000056351A3 true WO2000056351A3 (en) 2001-01-11

Family

ID=23042179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006202 WO2000056351A2 (en) 1999-03-19 2000-03-10 Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms

Country Status (2)

Country Link
AU (1) AU3735100A (en)
WO (1) WO2000056351A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035554A2 (en) * 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035554A2 (en) * 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CALBO J ET AL: "Adenovirus-mediated introduction of wild-type p53 reinforces the cytotoxicity of gemcitabine in human pancreatic tumour cell lines.", DIGESTION, vol. 59, no. 3, May 1998 (1998-05-01), 30th European Pancreatic Club Meeting;Thessaloniki, Greece; June 10-13, 1998, pages 203 - 204, XP000946710, ISSN: 0012-2823 *
CASCALLO M ET AL: "Gemcitabine-Ad5CMVp53 combination treatment enhances the regression of human pancreatic tumors.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 863, XP002148897, ISSN: 0197-016X *
FENG L ET AL: "The role of p53 in nucleoside analog-induced apoptosis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 96, XP002148896, ISSN: 0197-016X *
KONECNY G ET AL: "Preclinical and clinical studies of combinations of chemotherapy with p53 tumor suppressor gene for ovarian cancer.", EUROPEAN JOURNAL OF CANCER, vol. 35, no. SUPPL. 5, October 1999 (1999-10-01), 5th International Symposium on the Biological Therapy of Cancer: From Basic Research to Clinical Applications;Munich, Germany; October 27-30, 1999, pages S37, XP000946696, ISSN: 0959-8049 *

Also Published As

Publication number Publication date
AU3735100A (en) 2000-10-09
WO2000056351A2 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO1999064576A3 (en) Human genes differentially expressed in colon cancer
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
WO2000012702A3 (en) Human genes differentially expressed in colorectal cancer
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000056351A3 (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase